Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TLX with free AI briefings, catalyst countdowns, and dilution alerts.

TLX · Telix Pharmaceuticals Ltd

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$251.9M Cash on Hand
251.8mo Cash Runway
Follow TLX by email Get an email when TLX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TLX, unsubscribe in one click. Privacy

📣 What TLX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
177Lu-TLX591 Metastatic Castration-resistant Prostate Cancer Phase 3 · NCT06520345 Recruiting
Gallium Ga 68 Gozetotide Prostate Cancer Phase 3 · NCT05744115 Terminated
F-18 Fluoroethyltyrosine Brain Metastasis Phase 3 · NCT07931261 Not yet recruiting
Zirconium Zr 89 Girentuximab Clear Cell Renal Cell Carcinoma Phase 3 · NCT06750419 Recruiting
ArabinoFuranosylGuanine [18F]F-AraG Advanced Cancer Phase 1/2 · NCT05663710 Recruiting
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC Prostate Cancer Phase 2 · NCT04402151 Recruiting
Fluciclovine F18 Prostate Adenocarcinoma Phase 2 · NCT03762759 Active not recruiting
177Lu-TLX250 ccRCC Phase 2 · NCT07870746 Not yet recruiting
Lutetium Lu 177 Rosopatamab Tetraxetan Prostate Cancer Phase 2 · NCT05146973 Completed
177Lu girentuximab Advanced Cancer Phase 1/2 · NCT05663710 Recruiting
Iodine I 131 IPA Neoplastic Disease Phase 1 · NCT05450744 Active not recruiting
89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) Soft Tissue Sarcoma Phase 1 · NCT06537596 Recruiting
68-Ga PSMA11 Prostate Adenocarcinoma Phase 1 · NCT06044857 Recruiting
Samarium Sm 153-DOTMP Bone Pain Phase 1 · NCT07197645 Recruiting
Drug: 68-Ga PSMA11 Prostate Cancer Early Phase 1 · NCT07674771 Not yet recruiting
Copper Cu 64-DOTA-TLX592 Metastatic Prostate Cancer Early Phase 1 · NCT04726033 Completed

Also used in these trials (approved or third-party drugs, not TLX's own candidates): Enzalutamide, Abiraterone Acetate, Docetaxel Anhydrous, Nivolumab, Cabozantinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TLX holds $251.9M in cash and short-term investments and burns about $3M/quarter from operations, an estimated runway of 251.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TLX files for a raise →

👥 Who Owns TLX

Insiders 7.5% Institutions (82 holders) 1.1% Public and other holders 91.4%
HolderTypeShares% of sharesAs of
Christian Behrenbruch
MD & Group CEO, Director
Insider 20,742,935 6.12% 2026-04-28
Mark Alexander Nelson
Director
Insider 3,628,750 1.07% 2026-03-18
Jann Elizabeth Skinner
Director
Insider 595,000 0.18% 2026-03-18
David Norman Cade
Group Chief Medical Officer
Insider 373,133 0.11% 2026-03-18
Darren Charlton Smith
Group Chief Financial Officer
Insider 13,992 0.00% 2026-09-07
Marie Elizabeth McDonald
Director
Insider 3,719 0.00% 2026-03-18
Darren Joel Patti
Group Chief Operating Officer
Insider 804 0.00% 2026-03-18

Share count 338,777,049 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TLX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TLX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.